Injectable antibiotics are key to any treatment regimen for multi-drug resistant tuberculosis, according to PLoS Medicine. Changes among the producers have resulted in single manufacturers supplying global demand in some cases. The treatment regimen has been "plagued with drug shortages for many years due to this situation."
To identify the "worst" shortages, Fox of DIS says to look for shortages where there is just one supplier of the drug. Among candidates for the worst, she cites drugs and substances used every day in hospitals: electrolytes and calcium, for example.
- Tobramycin Injection; Akorn, APP, Hospira, Teva, Pfizer
- Cefotetan Disodium Injection; APP, B Braun
- Cefpodoxime; Aurobindo, Ranbaxy
- Mitomycin Injection; Bedford, Accord
- Daunorubic Hydrochloride Injection; Bedford, Teva
- Vancomycin HCL Injection; Bioniche, Akorn, Pfizer, APP, Hospira
- Metronidazole Injection; Claris, West-ward
- Ticarcillin Clavulanate; GlaxoSmithKline
- Streptozocin for Injection; Teva
- Metronidazole tablets; Teva, Watson